The Beijing Research Institute was established in early 2020 and is led by Dr. Lin Zhaosheng, a returned scientist with more than 20 years of experience in biopharmaceutical research and development. It mainly focuses on the design and development of peptide protein drugs, especially the design and establishment of long-acting platforms and the development of oral dosage forms.

The Beijing Research Institute possesses four core technology platforms: a high-expression platform for recombinant genetically engineered bacteria, a tool enzyme platform, an oral macromolecular drug delivery platform, and a platform for innovative biological drug molecules (drug screening and drugability assessment). Leveraging these platforms, projects such as semaglutide and its injection, the innovative single-target GLP-1 agonist HSP001, the innovative dual-target agonist HSP012C, the innovative triple-target agonist HSP016, the innovative long-acting insulin, the oral GLP-1, and the tool enzyme projects are progressing smoothly.

Over the next 5-10 years, the Beijing Research Institute will focus on developing innovative mono- and dual-agonist peptide drugs with long-acting (once-weekly) properties, oral administration, and weight loss capabilities to serve patients with type 2 diabetes. With innovation at its core and demand as its guiding principle, the institute will continuously pursue breakthroughs, aiming to build a modern, high-tech biopharmaceutical R&D enterprise. Through an internationalized and standardized operational model, the institute will contribute innovative drugs to society.